Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Glaxosmithkline (GSK) Share Price

Price 1,983.00p on 26-06-2026 at 16:35:50
Change -0.50p -0.03%
Buy 1,979.50p
Sell 1,978.50p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Unknown 2,896,693.00 at 1,972.50p
Day's Volume: 13,837,274
Last Close: 1,983.00p
Open: 1,972.50p
ISIN: GB00BN7SWP63
Day's Range 1,945.50p - 1,995.50p
52wk Range: 1,315.00p - 2,282.00p
Market Capitalisation: £79.45b
VWAP: 1,978.19441p
Shares in Issue: 4.01b

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Higher Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Glaxosmithkline (GSK) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 2,896,693 1,972.50p Negotiated Trade
OTC Trade
 17:12:52 - 26-Jun-26
Buy* 9,126 1,983.00p SI Trade
Negotiated Trade
 16:51:12 - 26-Jun-26
Buy* 116 1,983.00p SI Trade
Negotiated Trade
 16:51:12 - 26-Jun-26
Buy* 25,692 1,983.00p SI Trade
Negotiated Trade
 16:51:12 - 26-Jun-26
Sell* 33,170 1,983.00p Automatic Execution
 16:38:39 - 26-Jun-26
Sell* 200 1,983.00p Automatic Execution
 16:38:39 - 26-Jun-26
Sell* 200 1,983.00p Automatic Execution
 16:38:39 - 26-Jun-26
Sell* 200 1,983.00p Automatic Execution
 16:38:39 - 26-Jun-26
Sell* 200 1,983.00p Automatic Execution
 16:38:39 - 26-Jun-26
Sell* 200 1,983.00p Automatic Execution
 16:38:39 - 26-Jun-26
See more Glaxosmithkline trades

Glaxosmithkline (GSK) Share Price History

Time period:
to
Date Open High Low Close Volume
26th Jun 2026 (Fri) 1,972.50 1,995.50 1,945.50 1,983.00 13,837,274
25th Jun 2026 (Thu) 1,949.00 1,991.00 1,926.50 1,983.50 8,999,065
24th Jun 2026 (Wed) 1,967.00 1,984.00 1,950.00 1,950.00 5,923,852
23rd Jun 2026 (Tue) 1,915.00 1,971.00 1,911.00 1,957.50 8,305,282
22nd Jun 2026 (Mon) 1,925.00 1,931.50 1,912.00 1,924.50 3,565,700
19th Jun 2026 (Fri) 1,926.00 1,943.00 1,917.00 1,925.50 15,135,955
18th Jun 2026 (Thu) 1,976.00 1,978.50 1,906.00 1,923.00 7,565,324
17th Jun 2026 (Wed) 1,948.50 1,974.00 1,935.50 1,972.50 4,713,165
16th Jun 2026 (Tue) 1,955.50 1,968.00 1,940.50 1,950.00 6,759,168
15th Jun 2026 (Mon) 1,984.00 1,988.50 1,953.50 1,958.00 7,052,610
12th Jun 2026 (Fri) 1,963.50 2,011.00 1,960.00 1,984.00 5,538,575
11th Jun 2026 (Thu) 1,914.00 1,973.00 1,910.50 1,962.50 7,722,952
10th Jun 2026 (Wed) 1,915.50 1,929.00 1,890.50 1,921.50 6,411,067
9th Jun 2026 (Tue) 1,888.00 1,912.00 1,839.00 1,903.50 9,721,895
8th Jun 2026 (Mon) 1,936.50 1,942.50 1,904.50 1,913.00 4,169,869
5th Jun 2026 (Fri) 1,915.50 1,940.00 1,908.00 1,938.00 6,350,731
4th Jun 2026 (Thu) 1,859.50 1,904.00 1,859.00 1,902.00 12,974,263
3rd Jun 2026 (Wed) 1,817.50 1,856.50 1,813.00 1,851.50 8,183,347
2nd Jun 2026 (Tue) 1,840.00 1,842.00 1,805.00 1,820.50 6,580,750
1st Jun 2026 (Mon) 1,866.00 1,882.00 1,832.50 1,842.50 4,511,279
29th May 2026 (Fri) 1,919.50 1,920.50 1,881.50 1,881.50 20,433,488
28th May 2026 (Thu) 1,921.50 1,935.50 1,905.50 1,918.00 6,885,741
27th May 2026 (Wed) 1,893.50 1,943.00 1,893.50 1,939.50 5,898,532
See more Glaxosmithkline price history

Glaxosmithkline (GSK) Regulatory News

Date Source Headline
26th Jun 2026 3:00 pm RNS Holding(s) in Company
24th Jun 2026 3:30 pm RNS Director/PDMR Shareholding
24th Jun 2026 2:52 pm RNS GSK announces tender offer to acquire Nuvalent
23rd Jun 2026 3:30 pm RNS Director/PDMR Shareholding
22nd Jun 2026 3:00 pm RNS Transaction in Own Shares
17th Jun 2026 4:06 pm RNS cUTI oral antibiotic Tebipenem approved by US FDA
15th Jun 2026 3:00 pm RNS Transaction in Own Shares
12th Jun 2026 7:00 am RNS Momelotinib orphan drug designations for VEXAS
11th Jun 2026 3:30 pm RNS Director/PDMR Shareholding
10th Jun 2026 3:30 pm RNS Director/PDMR Shareholding
See more Glaxosmithkline regulatory news

Glaxosmithkline (GSK) Share News

GSK launches tender offer for USD10.6 billion purchase of Nuvalent

24th Jun 2026 15:45

(Alliance News) - GSK PLC on Wednesday said it has launched the tender offer for its previously announced acquisition of US-based cancer drug developer Nuvalent Inc for USD10.6 billion. Read More

IN BRIEF: GSK executives, including non-exec chair, buy shares

23rd Jun 2026 20:20

GSK PLC - London-based pharmaceuticals firm - Non-Executive Chair Jonathan Symonds buys 1,550 shares at GBP19.35 for total GBP29,992.50 last Friday. Director Vishal Sikka buys 1,266 ADS for USD50.69 each, for total USD64,175 on Monday, and Director Charles Bancroft buys 1,855 ADS for USD50.69 each, total USD94,031, also on Monday Read More

GSK says US FDA approves urinary tract infection treatment Utebzi

17th Jun 2026 21:36

(Alliance News) - GSK PLC and Spero Therapeutics Inc on Wednesday said that the US Food & Drug Administration has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections. Read More

GSK drug momelotinib gains regulatory nods as VEXAS treatment

12th Jun 2026 10:05

(Alliance News) - GSK PLC on Friday announced that momelotinib has received orphan drug designation from the US Food & Drug Administration, and the European Medicines Agency, to treat VEXAS syndrome. Read More

LONDON BRIEFING: UK economy contracts in April; Flutter to leave LSE

12th Jun 2026 07:58

(Alliance News) - The UK economy contracts 0.1% in April, Flutter Entertainment says it will delist from the London Stock Exchange in August, while Alternative Income REIT's largest shareholder makes a takeover bid. Read More

See more Glaxosmithkline news
FTSE 100 Latest
Value10,508.02
Change-21.87

Login to your account

Forgot Password?

Not Registered